John Blankenhorn is a journalist and writer for InvestorPlace, specializing in the stock market and investment opportunities. With a focus on biotech, artificial intelligence, and emerging technologies, John provides insights and analysis on potential investment options for readers.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
John's articles focus on investment analysis and announcements related to biotechnology, finance, scientific advancements, healthcare & pharmaceuticals. He typically covers stocks and trends within these sectors.
If you're considering reaching out to John Blankenhorn, ensure that your pitches are tailored towards providing in-depth investment analysis or announcing significant developments within the fields of biotechnology, finance, scientific advancements or healthcare & pharmaceuticals. The content should be data-driven and provide valuable insights for investors interested in these specific industries.
Since John does not have a specified geographic focus but instead focuses on global stock market trends and company-specific analyses across various industries mentioned above, it is essential to present him with well-researched information along with supporting data about the companies or industry developments being pitched.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: John Blankenhorn
The industries of the future are already available for investing today. Don't get left behind as synthetic biology stocks build the future.
Biotech stocks are still below their post-pandemic peaks. But these beaten-down biotech stocks could lead the sector to new highs.
These three flying car stocks are pushing aggressive timetables with proven aircraft. They may be taking you to your next meeting.
The AI revolution is bringing big gains to machine learning stocks. Here are three of the best to buy right now.
By: John Blankenhorn
Ginkgo Bioworks, Recursion Pharmaceutical, and Eli Lilly are cashing in on the AI-Biotech trend of tomorrow using the big data of today.
The best drug stocks to buy now are shooting for the moon. These three trailblazers will land among the stars.
These biotech stocks, Thermo Fisher, Novo Nordisk, and Eli Lilly, will bring consistent returns in the volatile biotech sector.
These top three biotech companies are ready to roar into the new year with promising new trials, drugs, and innovative use of AI.
By: John Blankenhorn
These are three of the top battery stocks bringing products of the future to solve the problems of today. Consider picking them up now.
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.
(833) 317-6278 
